Background {#Sec1}
==========

Gastric cancer is a severe problem worldwide. It is the fourth most common cancer and the second leading cause of cancer death globally. According to recent reports, nearly 950,000 new cases are diagnosed each year, and 720,000 patients with gastric cancer died from gastric cancer in 2012 \[[@CR1], [@CR2]\]. Although gastric cancer is not a common cancer in North America or most Western European areas, the burden of gastric cancer is still very high in Eastern Asia, Central and Eastern Europe, and Latin America \[[@CR3]\]. Specifically, more than 50% of patients arise in the Eastern Asian area.

Surgery is the mainstay in the multidisciplinary treatment for gastric cancer. Adequate surgical resection is the only potentially curative method for gastric cancer \[[@CR4], [@CR5]\]. Surgery for gastric cancer must ensure the complete removal of the tumor and potentially metastatic lymph nodes. Meanwhile, the intraoperative and postoperative safety and postoperative quality of life should be under consideration before surgeons determine the surgical treatment strategy. The extent of surgical resection is determined by tumor stage, location, size, histological type and some other clinicopathological characteristics. An adequate gastrectomy is defined as complete resection of the primary tumor with negative resection margins. According to the latest Japanese gastric cancer treatment guidelines published in 2016, the standard surgical procedure for tumor with clinically positive lymph nodes or tumor invading to or deeper than the muscularis propria is either distal subtotal gastrectomy or total gastrectomy \[[@CR6], [@CR7]\]. Distal subtotal gastrectomy could be selected when a satisfactory proximal resection margin can be achieved. As a result, for tumors located in the upper third of the stomach, proximal subtotal gastrectomy or total gastrectomy is recommended, depending on the depth of tumor invasion \[[@CR8]\]. With regard to lower-third gastric cancer, distal subtotal gastrectomy is the optimal surgical procedure suggested by previous studies \[[@CR9], [@CR10]\]. Nonetheless, the extent of gastrectomy for middle-third gastric cancer remains controversial. Some studies have recommended total gastrectomy as the standard procedure because of its potential for improved long-term survival \[[@CR11], [@CR12]\]. Considering the better intraoperative and postoperative safety and quality of life, distal subtotal gastrectomy has been reported to be an alternatively curative treatment for middle-third gastric cancer \[[@CR13]\].

The short-term effect and long-term prognosis of different extents of gastrectomy for middle-third gastric cancer have not been well evaluated until now. In our study, we therefore analyse the intraoperative and postoperative effects and long-term survival outcomes of patients with middle-third gastric cancer who underwent different extents of gastrectomy.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

This study is carried out under the approval of the Ethics Committee of Peking University Cancer Hospital. Each patient within this study signed informed consent. We retrospectively collect clinicopathological data from a prospectively collected database at the Peking University Cancer Hospital. Between January 2005 and October 2011, a total of 339 patients with middle-third gastric adenocarcinoma who underwent curative resection are enrolled in our study. We adopt the Japanese definition of three regions of the stomach in this study. The stomach is anatomically divided into three portions, the upper, middle, and lower parts, by lines connecting the trisected points on the lesser and greater curvatures. Tumors are described by the parts involved. If more than one part is involved, all involved portions are recorded in descending order of the degree of involvement, with the part containing the bulk of the tumor first \[[@CR14]\]. In our study, the centre of the primary tumor in all patients is located in the middle third of the stomach, and the tumors do not invade beyond the border between the upper and middle third of the stomach. In other words, all tumors are located in the middle third or middle-lower third of the stomach according to the Japanese classification of gastric carcinoma \[[@CR14]\]. The initial diagnosis was confirmed by endoscopic biopsy examination. Clinical staging was evaluated with ultrasound endoscopy of the stomach, abdominal and pelvic computed tomography scans, and laparoscopic exploration. The stage was classified based on the 7th edition Union for International Cancer Control (UICC)/American Joint Committee on Cancer (AJCC) TNM staging system \[[@CR7]\]. Patients with other types of gastric carcinoma, such as gastrointestinal stromal tumors or lymphoma, are excluded from this study.

Surgical treatments {#Sec4}
-------------------

All of the patients underwent laparoscopic exploration to exclude distant metastatic disease. After that, surgeons performed distal subtotal gastrectomy or total gastrectomy. The principle of surgery was mainly based on the Japanese gastric cancer treatment guidelines \[[@CR8], [@CR15]\]. Distal subtotal gastrectomy was a choice if a negative proximal resection margin could be obtained. The following rules of resection margin were adopted during the operation. The proximal resection margin was at least 3 cm for tumors invading to or deeper than the muscularis propria with an expansive growth pattern, or at least 5 cm for those with an infiltrative growth pattern. For tumors limited to mucosa or submucosa, a gross resection margin of 2 cm was obtained. If the above-mentioned criteria could not be fulfilled, frozen section examination of the proximal resection margin was completed to secure a negative resection margin. For cT1N0 tumors, D1 or D1+ lymph node dissection was conducted. For lymph node-positive or T2-T4 tumors, standard D2 lymph node dissection was performed.

Postoperative recovery was conducted by medical care professionals. Before the patient could leave the hospital, the discharge criteria had to be fulfilled. These criteria include the following: absence of subjective complaints, tolerance of solid oral intake, return of bowel function, absence of intravenous fluids/medications, adequate mobility of daily living and self-care (e.g., go to the toilet, dress, shower, etc.), adequate pain control on oral analgesia only, adequate wound condition, removal of the drainage tube, absence of infectious complications, absence of postoperative complications, absence of abnormal physical signs or laboratory tests (e.g., pulse, body temperature, white blood cell count, serum haemoglobin, etc.), acceptance of discharge, and an adequate home/social condition. In our study, adjuvant chemotherapy was carried out in patients who were identified as pathological T3/4 or metastasis in lymph nodes. Adjuvant chemotherapy was usually performed with cisplatin-based or 5-fluorouracil-based systemic therapy. However, radiotherapy was not used for all patients in our study.

Clinicopathologic parameters and follow-up {#Sec5}
------------------------------------------

The clinicopathological data collected from the database include the extent of gastrectomy, age, sex, body mass index (BMI), usage of neoadjuvant and adjuvant chemotherapy, degree of differentiation, presence of lymphovascular invasion, tumor size, tumor location, multi-tumor presence, depth of tumor invasion, number of harvested and metastatic lymph nodes, length of proximal resection margin, postoperative complications, reoperation, mortality, length of postoperative hospital stay, operation duration, blood loss volume, and survival outcome. The terminology used in this study is based on the Japanese classification of gastric carcinoma \[[@CR14]\]. Follow-up was carried out mainly by means of telephone interviews, E-mail communication, or outpatient reviews. The last follow-up was conducted on October 27, 2016.

Statistical analysis {#Sec6}
--------------------

All statistical analyses are performed using IBM SPSS Statistics 20.0 software (SPSS Inc., Armonk, NY). For quantitative variables, a normal distribution is verified. Variables with a normal distribution are expressed as the mean ± standard deviation and tested by a *t* test between groups. If not, the variables are expressed as medians with 25--75% ranges and tested by a Kruskal--Wallis non-parametric test. For categorical data, the chi-squared test or Fisher's exact test is performed. Kaplan--Meier estimation and log-rank tests are performed to compare survival. A Cox proportional hazards regression model is used to verify independent prognostic factors by univariate and multivariate analysis. *P* \< 0.05 (two-sided) is considered significant in the statistical analysis.

Results {#Sec7}
=======

Clinicopathologic parameters {#Sec8}
----------------------------

A total of 339 patients are enrolled in this retrospective study, and all of these patients are divided into a distal subtotal gastrectomy group (*n* = 144) or a total gastrectomy group (*n* = 195). The clinicopathological parameters are compared between the two groups. Age, sex, BMI, degree of differentiation and multi-tumor presence are comparable between the groups. More patients in the total gastrectomy group receive neoadjuvant chemotherapy (*P* \< 0.001). More patients in the total gastrectomy group have lymphovascular invasion (*P* = 0.015). Moreover, more patients in the total gastrectomy group are at a later T stage (*P* \< 0.001), N stage (*P* = 0.027), and have larger tumor size (*P* \< 0.001). More patients in the total gastrectomy group receive adjuvant chemotherapy (*P* \< 0.001). More patients in the distal subtotal gastrectomy group have tumors invading into the lower third of the stomach (*P* = 0.038; Table [1](#Tab1){ref-type="table"}). From these results, it seems that surgeons are inclined to choose total gastrectomy if the tumor is diagnosed as a relatively later-stage disease.Table 1Patients' clinicopathological parametersClinicopathological parametersDistal subtotal gastrectomy (*n* = 144), *n* (%)Total gastrectomy (*n* = 195), *n* (%)*P* valueGender0.641 Male94 (65)132 (68) Female50 (35)63 (32)Age0.354  ≤ 6087 (60)108 (55)  \> 6057 (40)87 (45)Body mass index0.797  \< 1919 (14)27 (14)  \~ \<2584 (60)111 (58)  \~ \<3031 (22)48 (25)  ≥ 305 (4)4 (2)Neoadjuvant chemotherapy\<0.001 No117 (81)123 (63) Yes27 (19)72 (37)Differentiation0.117 Well16 (11)21 (11) Moderate63 (44)67 (34) Poor65 (45)107 (55)Lymphovascular invasion0.015 No89 (63)96 (50) Yes52 (37)97 (50)Tumor size\<0.001  ≤ 5 cm109 (78)92 (47)  \> 5 cm31 (22)102 (53)Location0.038 Middle88 (61)140 (72) Middle-lower56 (39)55 (28)Multi-tumor0.699 No139 (98)192 (99) Yes3 (2)3 (1)Adjuvant chemotherapy\<0.001 Yes107 (74)186 (95) No37 (26)9 (5)T stage\<0.001 T137 (26)12 (6) T219 (14)11 (6) T33 (2)10 (5) T482 (58)182 (83)N stage0.027 N050 (39)52 (27) N126 (20)30 (16) N219 (15)32 (17) N333 (26)77 (40)

Intraoperative and postoperative parameters {#Sec9}
-------------------------------------------

Intraoperative and postoperative parameters are compared between the two groups (Table [2](#Tab2){ref-type="table"}). The results show that the length of proximal resection margin, blood loss volume, rate of reoperation and postoperative mortality have no significant differences between the two groups. In the total gastrectomy group, more lymph nodes are harvested. The median numbers of dissected lymph nodes in the distal subtotal gastrectomy and total gastrectomy groups are 26 and 31, respectively (*P* \< 0.001). Patients in the total gastrectomy group have a longer operative duration than those in the distal subtotal gastrectomy group. The median operation durations in the total gastrectomy and distal subtotal gastrectomy groups are 240 min and 180 min, respectively (*P* \< 0.001). Patients in the distal subtotal gastrectomy group have a shorter postoperative hospital stay. The median postoperative hospital stays in the distal subtotal gastrectomy and total gastrectomy groups are 12 days and 14 days, respectively (*P* = 0.001). Meanwhile, the rate of postoperative complications is lower in the distal subtotal gastrectomy group than in the total gastrectomy group (8% vs 15%, *P* = 0.047). Further analysis demonstrates that the rate of anastomosis leakage is lower in the distal subtotal gastrectomy group than in the total gastrectomy group (0% vs 4%, *P* = 0.023). The rates of bleeding, obstruction, peritoneal abscess, abdominal infection, pancreatic fistula and anastomosis stricture are all comparable between the groups (Table [2](#Tab2){ref-type="table"}).Table 2Patients' intraoperative and postoperative parametersIntraoperative and postoperative parametersDistal subtotal gastrectomyTotal gastrectomy*P* valueProximal resection margin, cm, median (25--75% range)5.0 (5.0--5.0)5.0 (4.0--6.0)0.939Total number of dissected lymph nodes, median (25--75% range)26 (18--34)31 (23--43)\<0.001Operation duration, min, median (25--75% range)180 (154--213)240 (190--270)\<0.001Blood loss volume, ml, median (25--75% range)150 (100--200)150 (100--200)0.178Postoperative hospital stay, days, median (25--75% range)12.0 (10--15.3)14.0 (11.0--19.5)0.001Complication rate, *n* (%)12 (8)29 (15)0.047Bleeding, *n* (%)2 (1)7 (4)0.311Anastomosis leakage, *n* (%)0 (0)8 (4)0.023Obstruction, *n* (%)1 (1)1 (1)1.000Peritoneal abscess, *n* (%)5 (4)13 (7)0.195Abdominal infection, *n* (%)6 (4)17 (9)0.100Pancreatic fistula, *n* (%)0 (0)4 (2)0.140Anastomosis stricture, *n* (%)0 (0)1 (1)1.000Reoperation, *n* (%)3 (2)7 (4)0.527Mortality rate, *n* (%)0 (0)3 (2)0.264

Survival results {#Sec10}
----------------

The median follow-up time is 41.8 months (range: 1--125 months). The overall survival is better in the distal subtotal gastrectomy group than in the total gastrectomy group (*P* \< 0.001; Fig. [1](#Fig1){ref-type="fig"}). The 5-year overall survival rates in the distal subtotal gastrectomy and total gastrectomy groups are 65% and 47%, respectively (*P* \< 0.001). In consideration of the clinicopathological differences existing between the groups, stage-stratified subgroup analysis is carried out. The 5-year survival rate is compared between the groups at the same pathological stage. In the subgroup analysis of patients with stage I, the 5-year survival rates in the distal subtotal gastrectomy and total gastrectomy groups are 91% and 94%, respectively (*P* = 0.759; Fig. [2a](#Fig2){ref-type="fig"}). For patients with stage II gastric cancer, the 5-year survival rates in the distal subtotal gastrectomy and total gastrectomy groups are 83% and 66%, respectively (*P* = 0.075; Fig. [2b](#Fig2){ref-type="fig"}). In the subgroup analysis of patients with stage III gastric cancer, the 5-year survival rates in the distal subtotal gastrectomy and total gastrectomy groups are 40% and 33%, respectively (*P* = 0.203; Fig. [2c](#Fig2){ref-type="fig"}). The results demonstrate that the 5-year survival rates are comparable between the distal subtotal gastrectomy and total gastrectomy groups at the same stage.Fig. 1Overall survival curves of patients in the distal subtotal gastrectomy and total gastrectomy groups. Overall survival is better in the distal subtotal gastrectomy group than the total gastrectomy group. The 5-year survival rates in the distal subtotal gastrectomy and total gastrectomy groups are 65% and 47%, respectively (*P* \< 0.001) Fig. 2Stage-stratified survival curves of patients in the distal subtotal gastrectomy and total gastrectomy groups. In stage-stratified subgroup analysis of stage I, the 5-year survival rates in the distal subtotal gastrectomy and total gastrectomy groups are 91% and 94%, respectively (*P* = 0.759; (**a**). For patients at stage II, the 5-year survival rates in the distal subtotal gastrectomy and total gastrectomy groups are 83% and 66%, respectively (*P* = 0.075; **(b**). In the subgroup analysis of stage III, the 5-year survival rates in the distal subtotal gastrectomy and total gastrectomy groups are 40% and 33%, respectively (*P* = 0.203; (**c**)

All of the clinicopathological and perioperative parameters are included in the univariate analysis to identify the prognostic factors for survival. The results show that the extent of gastrectomy (*P* \< 0.001), tumor location (*P* = 0.006), degree of differentiation (*P* = 0.019), blood loss volume (*P* = 0.005), age (*P* = 0.002), operation duration (*P* \< 0.001), complications (*P* = 0.015), usage of neoadjuvant chemotherapy (*P* \< 0.001), tumor size (*P* \< 0.001), presence of lymphovascular invasion (*P* \< 0.001), usage of adjuvant chemotherapy (*P* \< 0.001), T stage (*P* \< 0.001) and N stage (*P* \< 0.001) are all prognostic factors for survival (Table [3](#Tab3){ref-type="table"}). Since the usage of adjuvant chemotherapy is highly correlated with the pathological T stage and N stage, it is not included in the multivariate analysis. Subsequently, the above-mentioned factors are included in a multivariate analysis. The results show that age (*P* = 0.046), operation duration (*P* \< 0.001), complications (*P* = 0.037), usage of neoadjuvant chemotherapy (*P* \< 0.001), tumor size (*P* = 0.012), presence of lymphovascular invasion (*P* = 0.043) and N stage (*P* \< 0.001) are all independent prognostic factors for survival (Table [4](#Tab4){ref-type="table"}).Table 3Univariate analysis of prognostic factors for survivalVariableUnivariate, hazard ratio (95% Confidence interval)*P* valueGenderMale10.531Female0.898 (0.641, 1.258)Body mass index\<1910.841\~ \< 250.990 (0.626, 1.565)0.964\~ \< 301.095 (0.656,1.830)0.728≥300.665 (0.200,2.217)0.507Postoperative hospital stay1.001 (0.990, 1.012)0.895ReoperationNo10.726Yes1.172 (0.481, 2.859)Multi-tumorNo10.147Yes0.259 (0.036, 1.850)Total number of dissected lymph nodes1.008 (0.999, 1.018)0.086Proximal resection margin0.943 (0.851, 1.044)0.257GastrectomyDistal subtotal gastrectomy1\<0.001Total gastrectomy1.894 (1.359, 2.640)LocationMiddle10.006Middle-lower1.565 (1.137, 2.153)DifferentiationWell10.019Moderate1.032 (0.580, 1.837)0.914Poor1.609 (0.932, 2.780)0.088Blood loss volume1.001 (1.000, 1.002)0.005Age≤6010.002\>601.654 (1.210, 2.260)Operation duration1.003 (1.001, 1.005)\<0.001ComplicationsNo10.015Yes1.708 (1.104, 2.642)Neoadjuvant chemotherapyNo1\<0.001Yes1.791 (1.297, 2.475)Adjuvant ChemotherapyNo1\<0.001Yes10.850 (3.459, 34.033)Tumor size≤5 cm1\<0.001\>5 cm2.828 (2.052, 3.897)Lymphovascular invasionNo1\<0.001Yes2.622 (1.902, 3.615)T stageT11\<0.001T23.961 (1.024, 15.322)0.046T39.944 (2.485, 39.790)0.001T412.988 (4.136, 40.782)\<0.001N stageN01\<0.001N12.542 (1.425, 4.532)0.002N23.045 (1.690, 5.487)\<0.001N36.562 (4.017, 10.719)\<0.001 Table 4Multivariate analysis of prognostic factors for survivalVariablehazard ratio (95% Confidence interval)*P* valueGastrectomyDistal subtotal gastrectomy10.942Total gastrectomy1.015 (0.677, 1.523)LocationMiddle10.271Middle-lower1.219 (0.857, 1.735)DifferentiationWell10.315Moderate1.218 (0.644, 2.302)0.544Poor1.506 (0.813, 2.791)0.193Blood loss volume1.001 (1.000, 1.002)0.094Age≤6010.046\>601.401 (1.006, 1.950)Operation duration1.004 (1.002, 1.006)\<0.001ComplicationsNo10.037Yes1.668 (1.031, 2.698)Neoadjuvant chemotherapyNo1\<0.001Yes1.938 (1.362, 2.756)Tumor size≤5 cm10.012\>5 cm1.581 (1.108, 2.257)Lymphovascular invasionNo10.043Yes1.476 (1.012, 2.151)T stageT110.069T20.865 (0.183, 4.094)0.855T32.093 (0.487, 8.995)0.321T42.712 (0.790, 9.311)0.113N stageN01\<0.001N12.234 (1.165, 4.284)0.016N22.236 (1.149, 4.349)0.018N34.416 (2.417, 8.067)\<0.001

Discussion {#Sec11}
==========

Surgery is the only potentially curative method for patients with gastric cancer. The ideal surgical resection not only achieves the curative intent but also decreases postoperative morbidity and mortality. The long-term prognosis and postoperative quality of life should both be of great concern \[[@CR12], [@CR16], [@CR17]\]. Considering that distal subtotal gastrectomy is associated with a better quality of life and lower morbidity and mortality, many surgeons recommend distal subtotal gastrectomy as the optimal procedure for lower-third gastric cancer based on previous reports \[[@CR18]--[@CR20]\]. However, at the moment, there is no consensus regarding the best extent of gastrectomy for middle-third gastric cancer. The only prospective randomized trial, performed in Italy, compared surgical morbidity and long-term prognosis between distal subtotal gastrectomy and total gastrectomy for patients with gastric cancer. However, only approximately 20% of patients in that study had middle-third gastric cancer \[[@CR10], [@CR21]\]. The conclusions in that study might not be appropriate for patients with middle-third gastric cancer. Until now, many surgeons have preferred to perform total gastrectomy for relatively later-stage middle-third gastric cancer to ensure the curativeness of the surgery. In our study, the proportion of relatively later-stage cases is higher in the total gastrectomy group than in the distal subtotal gastrectomy group. This result is concordant with previous reports \[[@CR13], [@CR22]\].

In our study, the total number of harvested lymph nodes is higher in the total gastrectomy group than in the distal subtotal gastrectomy group (*P* \< 0.001). The primary reason is that we perform standard D2 lymph node dissection for locally advanced gastric cancer. During distal subtotal gastrectomy, the D2 lymph node dissection includes group 1, 3, 4sb, 4d, 5, 6, 7, 8a, 9, 11p and 12a lymph nodes. With regard to the total gastrectomy procedure, the scope of D2 lymph node dissection should include the above-mentioned groups and add group 2, 4sa, 10 and 11d lymph nodes \[[@CR8], [@CR15], [@CR23]\]. Therefore, more harvested lymph nodes in the total gastrectomy group is reasonable. Although there are more harvested lymph nodes in the total gastrectomy group than in the distal subtotal gastrectomy group, the total gastrectomy procedure is more complicated than distal subtotal gastrectomy. Therefore, total gastrectomy consumes more time and induces more postoperative complications and longer postoperative hospital stay. In our study, the median operative durations in the total gastrectomy and distal subtotal gastrectomy groups are 240 min and 180 min, respectively (*P* \< 0.001). Similarly, postoperative hospital stay is longer in the total gastrectomy group than in the distal subtotal gastrectomy group (*P* = 0.001). Notably, the complication rate is higher in the total gastrectomy group than in the distal subtotal gastrectomy group. Further analysis by splitting the different complications elucidates that the rate of anastomosis leakage is higher in the total gastrectomy group than in the distal subtotal gastrectomy group. Previous studies obtained similar conclusions \[[@CR21], [@CR24]\]. The main explanation for this is that the oesophago-jejunal anastomosis is more fragile than the gastro-jejunal anastomosis. The fragility of the oesophago-jejunal anastomosis leads to a higher rate of anastomosis leakage.

The effect on long-term survival of the different gastrectomy procedures has received the most attention for a long time. In our study, overall survival in the distal subtotal gastrectomy group is better than that in the total gastrectomy group, and the 5-year survival rates in the distal subtotal gastrectomy and total gastrectomy groups are 65% and 47%, respectively (*P* \< 0.001). Given the imbalance in tumor staging between the groups, we perform stage-stratified subgroup analysis to compare the survival outcomes. In the stage-stratified analysis, the 5-year survival rates are comparable between the groups. The results demonstrate that the difference in 5-year survival rate between the distal subtotal gastrectomy and total gastrectomy groups is mainly induced by the imbalance of tumor staging. This result is also concordant with previous reports \[[@CR22], [@CR25]\].

To determine the prognostic factors for survival, univariate and multivariate analyses are performed. The results show that N stage (*P* \< 0.001), tumor size (*P* = 0.012), presence of lymphovascular invasion (*P* = 0.043), operation duration (*P* \< 0.001), complications (*P* = 0.037), age (*P* = 0.046) and usage of neoadjuvant chemotherapy (*P* \< 0.001) are independent prognostic factors for survival. N stage, tumor size, presence of lymphovascular invasion and usage of neoadjuvant chemotherapy all directly or indirectly represent the degree of tumor progression and TNM staging. Thus, the result that these factors could affect survival outcomes is reasonable. In our study, complication is an independent prognostic factor for survival, as also reported in previous reports \[[@CR10], [@CR25]\]. Interestingly, the proximal resection margin and extent of gastrectomy are not prognostic factors for survival. In fact, many surgeons prefer to perform total gastrectomy for patients with middle-third gastric cancer to make sure that they achieve a safe proximal resection margin. In previous studies as well as in our study, only if an R0 resection is achieved would the distance from the resection margin to the tumor border not affect survival outcome \[[@CR22], [@CR26]\]. Meanwhile, the extent of gastrectomy is also not an independent factor for survival. In other words, distal subtotal gastrectomy would be a rational choice for patients with middle-third gastric cancer if an R0 resection could be achieved.

Some limitations exist in our study. This study is a retrospective study, and selection bias is difficult to avoid. For example, the proportions of patients with larger tumor size, lymphovascular invasion, neoadjuvant and adjuvant chemotherapy or later-stage disease are higher in the total gastrectomy group than in the distal subtotal gastrectomy group. These factors all represent a likely later-stage disease. The choice of the gastrectomy procedure's extent is decided by surgeons, who usually choose total gastrectomy for patients with later-stage disease, as total gastrectomy seems to be a more effective and safe means to achieve a curative resection. However, stage-stratified subgroup analysis and multivariate analysis are performed in our study. The results of this study remain convincing. In the future, a prospective randomised controlled study is needed to further clarify the best extent of gastrectomy for patients with middle-third gastric cancer.

Conclusions {#Sec12}
===========

For patients with middle-third gastric cancer, distal subtotal gastrectomy shortens operation duration and postoperative hospital stay and reduces postoperative complications. At the same time, the long-term survival of patients with distal subtotal gastrectomy is similar to that of those with total gastrectomy at the same stage. The extent of gastrectomy for middle-third gastric cancer is not an independent prognostic factor for survival.
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